For a typical adult with established coronary artery disease requiring lifelong antiplatelet therapy and no contraindications, which is preferable for long‑term monotherapy: low‑dose aspirin (81 mg daily) or clopidogrel (75 mg daily)?

Clopidogrel 75 mg daily is the preferred long-term monotherapy for coronary artery disease

For adults with established coronary artery disease requiring lifelong antiplatelet monotherapy, clopidogrel 75 mg daily should be used instead of aspirin 81 mg daily. This recommendation is based on the most recent high-quality evidence demonstrating superior cardiovascular outcomes without increased bleeding risk.

Guideline Support

The 2024 ESC Guidelines explicitly state that clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin monotherapy in chronic coronary syndrome patients with prior MI or remote PCI (Class I, Level A recommendation) 1. This represents the highest level of evidence and recommendation strength. The guidelines position clopidogrel not merely as an "alternative for aspirin intolerance" but as an equivalent first-line option with Class I evidence.

The 2023 AHA/ACC Guidelines similarly acknowledge both agents but do not provide the same level of comparative guidance, focusing more on aspirin as the traditional standard 2.

Most Recent and Highest Quality Evidence

The 2025 individual patient data meta-analysis published in The Lancet (the single most important study to guide this decision) analyzed 28,982 patients across 7 randomized trials with median follow-up of 2.3 years 3. This study demonstrated:

• 14% relative risk reduction in major adverse cardiovascular or cerebrovascular events (MACCE) with clopidogrel vs aspirin (HR 0.86,95% CI 0.77-0.96; p=0.0082)
• No difference in major bleeding (HR 0.94,95% CI 0.74-1.21; p=0.64)
• No difference in mortality

This represents the highest quality synthesis of individual patient data available and directly answers the clinical question with clear superiority for clopidogrel.

Supporting Evidence from Real-World and Extended Follow-Up

A 2026 Korean nationwide real-world study of 18,168 patients followed for up to 10 years after DES implantation showed comparable overall outcomes but 29% reduction in myocardial infarction with clopidogrel (adjusted HR 0.71,95% CI 0.58-0.87; p=0.001) 4.

The HOST-EXAM Extended Study post-hoc analysis (2026) demonstrated that clopidogrel reduced the composite endpoint by 26-33% in both high ischemic risk and standard risk populations with no interaction between risk status and treatment effect 5.

Clinical Algorithm for Implementation

Start with clopidogrel 75 mg daily as default monotherapy for:

• Post-MI patients after completing DAPT
• Post-PCI patients after completing DAPT (typically 6-12 months)
• Patients with angiographically confirmed obstructive CAD

Switch from aspirin to clopidogrel in:

• Patients currently on aspirin who experience recurrent ischemic events
• Patients with peripheral artery disease or prior ischemic stroke (ESC IIb recommendation) 1
• Patients with aspirin-related GI intolerance or bleeding

Continue aspirin only if:

• Patient has been stable on aspirin for years with excellent adherence and no events
• Cost or access barriers make clopidogrel prohibitive
• Patient is a known clopidogrel non-responder (rare, requires genetic testing)

Important Caveats

Do not use a loading dose for chronic stable CAD. The FDA label specifies 75 mg daily without loading for established peripheral arterial disease, which applies to stable CAD 6. Loading doses (300-600 mg) are reserved for acute coronary syndromes 6.

Clopidogrel requires hepatic CYP2C19 activation. Approximately 2-15% of patients (depending on ethnicity) are poor metabolizers, though routine genetic testing is not currently recommended for stable CAD. Consider this if breakthrough events occur on clopidogrel.

The bleeding benefit is real but modest. While the Lancet meta-analysis showed no difference in major bleeding, a 2023 meta-analysis of 11,766 patients demonstrated 37% reduction in BARC major bleeding with clopidogrel (RR 0.63, p=0.02) 7. This makes clopidogrel particularly attractive in patients with prior bleeding history.

Reconciling Divergent Evidence

The 2026 Korean real-world study showed "comparable" overall outcomes but significant MI reduction 4, while the Lancet meta-analysis showed clear MACCE superiority 3. This apparent discrepancy reflects:

• Different follow-up durations (10 years vs 2.3 years median)
• Real-world adherence issues vs trial conditions
• The Korean study's composite endpoint included all-cause death (not just cardiovascular)

The Lancet individual patient data meta-analysis should take precedence as it represents the highest quality evidence synthesis with appropriate cardiovascular-specific endpoints.

Bottom Line

Clopidogrel 75 mg daily should replace aspirin as the default long-term antiplatelet monotherapy for coronary artery disease based on Class I guideline recommendations 1 and the most recent high-quality meta-analysis showing 14% MACCE reduction without increased bleeding 3. The evidence is strongest for post-MI and post-PCI populations but extends to all patients with established CAD requiring lifelong antiplatelet therapy.